Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrences
GH•Guardant Health disclosed published results from the prospective, multicenter COSMOS study, which found its Reveal blood test detected 81% of distant melanoma recurrences.
1. Study findings
The study evaluated Guardant Reveal in patients with resected stage II-III melanoma. Findings supported the test’s ability to identify patients at higher recurrence risk and detect relapse earlier than standard clinical identification; results also indicated strong accuracy among patients who remained recurrence-free.
